Primary Responsibilities Interpreting clinical data according to standard medical practice, GCP guidelines, protocol and charter definition and according to standard Clario SOPs and GCP for clinical trials. This in turn leads to fantastic customer service and allows us to transform patients’ lives. We want people who know their efforts are valued. We are investing resources to create an environment our people are proud to be a part of. It’s only through our people that we can continue to innovate technology that will shape the future of clinical trials. We value the contribution each of our people brings. We are united and driven by patients, committed to making a difference, and we are always looking for the best talent to help us transform lives. Bioclinica's global team of life science experts serve more than 500 pharmaceutical, biotechnology and device organizations – including the top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.At Clario, we put people first, always.
Clario bioclinica software#
Through deep medical, scientific and technology expertise, the company provides medical imaging and cardiac safety services clinical adjudication randomization and trial supply management and optimization electronic and eSource data capture site and patient payments clinical trial management software and drug safety solutions. Saliency's co-founders, Kevin Thomas, MD/PhD, candidate at Stanford University School of Medicine and Łukasz Kidziński, PhD, formerly of Stanford's Bioengineering & Statistics, will join Bioclinica's Image Science team, further strengthening the company's medical imaging expertise and offerings.īioclinica is an integrated clinical life science solutions provider, delivering powerful insight into clinical trial development, assuring greater client success in bringing medical therapies to market, for people around the world. The AI integration will create a perpetual learning system that will enable Bioclinica to expand its portfolio and drive new revenue with its enhanced offering. The Saliency acquisition solidifies Bioclinica's position as the premier global provider of research image technology and services to sponsors and Clinical Research Organizations.
"We are proud to combine our state-of-the-art cloud-based tools with Bioclinica's unrivaled imaging expertise," added Łukasz Kidziński, PhD, Saliency's President and CTO. "This integration empowers industry stakeholders with the absolute latest in medical imaging technology by delivering custom AI models faster and with more accuracy," said Kevin Thomas, MD/PhD, CEO of Saliency. This capability will be embedded into Bioclinica's current and future imaging solutions in accordance with EU GDPR and other privacy regulations. These newly created models can then be used to accurately and efficiently screen, redact, or interpret medical images to support a wide range of therapeutic areas. The Saliency platform uses proprietary algorithms to quickly build and train AI models from a small number of de-identified images. "We evaluated a variety of medical imaging AI platforms and know the Saliency platform is head and shoulders above others in the market in its ability to deliver value for our clients." "Clients rely on us for time-sensitive expert-level image interpretation for their clinical trials so they can focus on outcomes," said Dan Gebow, PhD, Chief Innovation Officer at Bioclinica. The integration will dramatically accelerate image QC and interpretation, enabling rapid development of digital diagnostics and digital therapeutics. Bioclinica will integrate the company's advanced AI technology into its Imaging Platform to support a growing portfolio of pharmaceutical and medical device clients. 6, 2021 /PRNewswire/ - Bioclinica, an integrated solutions provider of clinical life science and technology expertise, today announced that it has acquired Silicon Valley-based Saliency.
0 kommentar(er)
